A signal-seeking phase 2 study of Trastuzumab emtansine in tumours harbouring HER2 amplification or mutation-Reference-Cited by-同舟云学术

A signal-seeking phase 2 study of Trastuzumab emtansine in tumours harbouring HER2 amplification or mutation

Published:2024-09-09 Issue:1 Volume:8 Page:
ISSN:2397-768X
Container-title:npj Precision Oncology
language:en
Short-container-title:npj Precis. Onc.

Author:

Thavaneswaran Subotheni^ORCID,Lin Frank^ORCID,Grady John P.,Espinoza David,Huang Min Li,Chinchen Sarah,Sebastian Lucille,Kansara Maya,Mersiades Tony,Lee Chee Khoon,Desai Jayesh^ORCID,Grimison Peter,Brown Michael,Millward Michael,Harrup Rosemary,O’Byrne Ken,Nagrial Adnan,Craft Paul,Simes John^ORCID,Joshua Anthony M.,Thomas David M.

Funder

Australian Institute of Health and Welfare, Australian Government

Publisher

Springer Science and Business Media LLC

Link

https://www.nature.com/articles/s41698-024-00698-4.pdf

Reference46 articles.

1. Verma, S. et al. Trastuzumab Emtansine for HER2-positive advanced breast cancer. N. Engl. J. Med. 367, 1783–1791 (2012).

2. Gnant, M., Bartsch, R. & Steger, G. G. HER2-positive breast cancer: a new piece of the puzzle. Lancet Oncol. 15, 668–669 (2014).

3. Rugo, H. S. et al. Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer. ESMO Open 7, 100553 (2022).

4. Krop, I. E. et al. Trastuzumab emtansine versus treatment of physician’s choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. Lancet Oncol. 15, 689–699 (2014).

5. Krop, I. E. et al. Trastuzumab emtansine versus treatment of physician’s choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial. Lancet Oncol. 18, 743–754 (2017).